



# MARDIA SAMYOUNG

## CAPILLARY TUBES CO. LTD.



INDO-KOREAN JOINT VENTURE

MFRS. OF : BRASS & COPPER ALLOY RODS, BUSBARS, TUBES, SECTIONS & PROFILES ETC.

1304, Lodha Supremus, Senapati Bapat Marg, Lower Parel (W), Mumbai - 400 013 (INDIA).

Tel. No. : (022) 66251300-333, 8655606061/62/63

CIN No. L74999MH1992PLC069104

February 14<sup>th</sup>, 2025.

To  
Bombay Stock Exchange Ltd.  
Department of Corporate Services,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai 400 001

Dear Sir,

**SUB: OUTCOME OF BOARD MEETING DATED 14<sup>TH</sup> FEBRUARY, 2025**

We wish to inform that at the meeting of the Board of Directors of the Company held today i.e Friday, 14<sup>th</sup> February, 2025, the Board of Directors of the Company have considered and approved following;

1. The Un-audited Financial Results of the Company for the quarter ended 31<sup>st</sup> December, 2024.

The Statutory Auditors have carried out a "Limited Review" of the Un-audited Financial Results for quarter ended 31st December, 2024. In compliance with Regulation 33 & Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a copy of the Standalone Financial Results and Limited Review Report of the Statutory Auditors of the Company.

The Board Meeting commenced at 4.00 p.m. and concluded at 5:30 p.m.

Kindly take the same on your record.

Thanking you,

For **MARDIA SAMYOUNG CAPILLARY TUBES CO. LTD.**

**RAVINDRA MARDIA**  
**Managing Director**  
**DIN: 00077012**

# AGRAWAL & AGRAWAL ASSOCIATES

## CHARTERED ACCOUNTANTS

CA. Agrawal Shyam Sunder  
CA. Agrawal Ruchi  
CA. Elroy Lawrence Rodrigues

B.Com., F.C.A., L.L.B., DISA (ICAI)  
B.Com., A.C.A.  
B.Com., A.C.A., DISA (ICAI)



A-505, Eco Heights, Shree Nityanand Chs. Ltd.,  
Nityanand Nagar No. 1, Near Sanjeevani Hospital,  
Sahar Road, Andheri (E), Mumbai - 400069.  
Tel. : 2684 0916 | Telefax : 2683 5699  
E-mail : shyam31774@yahoo.com  
Website : www.cashyamagrawal.co.in  
Mobile : 9820052168, Off : 8928438391

### ANNEXURE V

#### LIMITED REVIEW REPORT

**Review Report to M/s. Mardia Samyoung Capillary Tubes Company Limited.**

We have reviewed the accompanying statement of unaudited financial results of M/s Mardia Samyoung Capillary Tubes Company Limited for the period ended 31.12.2024. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard of Review Engagement (SRE) 2400, engagements to Review Financial Statements performed issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (LODR) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For: Agrawal & Agrawal Associates**

**Chartered Accountants**

**Partner**

**Shyam C Agrawal**

**Date: 14/02/2025**

**Place: Mumbai**

**UDIN NO : 25031774BMGPOW1273**



**MARDIA SAMYOUNG CAPILLARY TUBES COMPANY LIMITED**  
**UNAUDITED FINANCIAL RESULTS FOR THE 3RD QUARTER ENDED 31.12.2024**  
**STATEMENT OF PROFIT AND LOSS (STANDALONE)**

CIN  
**NO.L74999MH1992PLC069104**

Rupees in Lakhs

	Particulars	QUARTER ENDED UN AUDITED 31.12.2024	QUARTER ENDED UN AUDITED 30.09.2024	QUARTER ENDED UNAUDITED 31.12.2023	YEAR TO DATE FOR CURRENT PERIOD ENDED 31.12.2024	YEAR TO DATE FOR PREVIOUS PERIOD ENDED 31.12.2023	YEAR ENDED AUDITED 31.03.2024
I	Income From Operations	0.00	0.58	0.00	12.33	0.00	0.00
II	Other Income	0.00	0.00	0.00	0.00	9.27	9.26
III	Total Income (I+II)	0.00	0.58	0.00	12.33	9.27	9.26
IV	<b>EXPENSES</b>	0.00	74.29	0.00	94.74	0.00	0.00
	Cost of materials consumed						
	Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods, Stock-in -Trade and work-in-progress	0.00	0.00	0.00	0.00	0.00	0.00
	Employee benefits expense	1.58	1.40	3.77	5.05	11.53	15.67
	Finance costs	0.00	0.00	0.00	0.00	0.00	0.00
	Depreciation and amortization expense	0.00	0.00	0.70	0.73	2.14	2.79
	Other expenses	3.29	67.45	7.43	77.22	12.51	41.78
	Total expenses (IV)	4.87	143.14	11.90	177.74	26.18	60.24
V	Profit/(loss) before exceptional items and tax (I- IV)	-4.87	-142.56	-11.90	-165.41	-16.91	-50.98
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit/(loss) before tax (V-VI)	-4.87	-142.56	-11.90	-165.41	-16.91	-50.98
VIII	Tax expense: (1) Current tax (2) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	-4.87	-142.56	-11.90	-165.41	-16.91	-50.98
X	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit/(loss) for the period (IX+XII)	-4.87	-142.56	-11.90	-165.41	-16.91	-50.98
XIV	Other Comprehensive Income A (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00



XV	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period	-4.87	-142.56	-11.90	-165.41	-16.91	-50.98
XVI	Earnings per equity share (for continuing operations) (1) Basic (2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XVII	Earnings per equity share (for discontinued operation): (1) Basic (2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XVIII	Earnings per equity share (for discontinued & continuing operations) (1) Basic (2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00

Notes:

1. The Above results for the quarter ended December 31st, 2024 were reviewed and recommended by the Audit Committed and subsequently approved by the Board of Directors in its Meeting held on 14th February 2025 and the same were also subject to Limited Review by Statutory Auditors of the Company.
2. The Figures for the previous financial period/year figures have re-classified/re-arranged/re-grouped wherever necessary to make them comparable.

By the Order of the Board

For Mardia Samyoung Capillary Tubes Co. Ltd.

  
Ravindra Mardia  
(Managing Director)

Place : Mumbai

Date : 14th February, 2025



For AGRAWAL & AGRAWAL ASSOCIATES  
Chartered Accountants

  
Partner  
FRN: 116653 W